6 independently-rated products may treat overweight, spanning FDA drug classes such as glp-1 receptor agonist, glucose-dependent insulinotropic polypeptide receptor agonist. The current highest-rated option is saxenda. All are ranked below by our independent rating — not medical advice; always consult a professional.
Top-rated picks for overweight: 1. Saxenda · 2. Wegovy · 3. Wegovy Hd
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Saxenda | Not yet rated | Prescription | — | View → |
| 2 | Wegovy | Not yet rated | Prescription | — | View → |
| 3 | Wegovy Hd | Not yet rated | Prescription | — | View → |
Treatment associations are derived from FDA drug-class data (RxClass “may treat”). This is general reference, not medical advice — always consult a licensed professional.
| 4 | Zepbound | Not yet rated | Prescription | — | View → |
| 5 | Zepbound (Autoinjector) | Not yet rated | Prescription | — | View → |
| 6 | Zepbound Kwikpen | Not yet rated | Prescription | — | View → |
Narrow by drug class
Full ranking · 6 treatments
PrescriptionFDA-sourced
Saxenda (liraglutide) is a once-daily GLP-1 receptor agonist injection approved for chronic weight management in adults with obesity (or overweight with a weight-related medical problem) and in adolescents aged 12 and older with obesity, used together with a reduced-calorie diet and increased physical activity.
Price varies
PrescriptionFDA-sourced
WEGOVY contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog).
PrescriptionFDA-sourced
WEGOVY contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog).
PrescriptionFDA-sourced
ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist.
PrescriptionFDA-sourced
ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist.
PrescriptionFDA-sourced
ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist.